Skip to main content
. 2009 Jan 22;100(2):251–258. doi: 10.1038/sj.bjc.6604877

Table 7. All-cause 60-day mortality.

  Arms A+C (no cetuximab)
Arm B (cetuximab)
  OxMdG XELOX OxMdG XELOX
No. of patients randomised 203 333 102 166
         
  N (%) N (%) N (%) N (%)
60-day all-cause mortality 12 (6%) 18 (5%) 5 (5%) 12 (7%)
Treatment-related death within 60 days 2 (1%) 2 (1%) 1 (1%) 3 (2%)